Brought to you by 
Astellas makes $52/share cash offer for OSI Pharmaceuticals
22 Mar 2012
Executive Summary
After over a year of attempting to enter into a friendly arrangement, Astellas Pharma has made a hostile bid to acquire top public biotech firm OSI Pharmaceuticals for $3.03bn in cash, or $52 a share (a 42% premium). In a written response on February 22, 2010, to Astellas' most recent oral proposal, OSI said the offer significantly undervalues the company and it is asking shareholders not to take any action. Astellas has filed a lawsuit to prevent OSI from conducting any activities, such as a "poison pill" plan that would interfere with the tender offer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Astellas makes $52/share cash offer for OSI Pharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice